Eli Lilly’s Weight-Loss Drug Demand Is Nearly Limitless. Here’s What Comes Next for the $1 Trillion Drugmaker
Eli Lilly just posted numbers that stunned Wall Street, but the company's own executives admit a single bottleneck could cap how far the GLP-1 juggernaut actually runs, and the next move to break through…



















